Sansure Biotech(SH:688289) Xin Lang Cai Jing·2026-01-05 02:57Core Viewpoint - Shengxiang Biotechnology has shown a mixed performance in stock price and financial results, with a recent increase in stock price but a decline in net profit year-on-year [1][2]. Financial Performance - As of September 30, 2025, Shengxiang Biotechnology reported a revenue of 1.244 billion yuan, representing a year-on-year growth of 20.49% [2]. - The net profit attributable to shareholders for the same period was 191 million yuan, which reflects a decrease of 2.10% compared to the previous year [2]. Stock Market Activity - On January 5, 2025, the stock price of Shengxiang Biotechnology increased by 2.06%, reaching 19.30 yuan per share, with a trading volume of 43.1 million yuan [1]. - The company has a total market capitalization of 11.182 billion yuan [1]. - The stock has experienced a 0.84% increase over the last five trading days, a 3.16% decrease over the last 20 days, and a 9.64% decrease over the last 60 days [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 21,600, up by 4.17% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 4.01% to 26,772 shares [2]. Dividend Distribution - Since its A-share listing, Shengxiang Biotechnology has distributed a total of 2.363 billion yuan in dividends, with 967 million yuan distributed over the last three years [3]. Institutional Holdings - As of September 30, 2025, the fourth largest circulating shareholder is Huabao Zhongzheng Medical ETF, holding 9.8053 million shares, a decrease of 1.7872 million shares from the previous period [3]. - Hong Kong Central Clearing Limited is a new shareholder, holding 3.6601 million shares [3].